---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-015373"
form_type: "8-K"
ticker: "XTNT"
cik: "0001453593"
company_name: "Xtant Medical Holdings, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:37:06.069122+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xtant Medical Q1 revenue up 38% to $17.9M; initiates FY2023 guidance $73-75M

## Summary
- Q1 2023 revenue of $17.9M, up 38% YoY (29% organic, 9% from Coflex acquisition).
- GAAP net loss improved to $2.1M ($0.02/shr) vs $2.2M ($0.03) in prior year.
- Non-GAAP adjusted EBITDA loss narrowed to $0.3M from $0.9M in Q1 2022.
- Full-year 2023 revenue guidance of $73M-$75M, representing 26%-29% annual growth.
- Gross margin expanded to 58.7% from 58.3%, driven by Coflex contribution.

## SEC filing metadata
- accession: 0001493152-23-015373
- form_type: 8-K
- ticker: XTNT
- cik: 0001453593
- company_name: Xtant Medical Holdings, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453593/000149315223015373/0001493152-23-015373-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453593/000149315223015373/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-015373
- JSON: https://secwatch.observer/filing/0001493152-23-015373.json
- Plain text: https://secwatch.observer/filing/0001493152-23-015373.txt

## Key facts
- Earnings Releases
  Xtant Medical Holdings, Inc. reported full year 2023 results: revenue $73 million to $75 million. Guidance initiated.
  - Period: full year 2023
  - Revenue: $73 million to $75 million
  - Guidance: initiated
  - Result: guidance update
  source text: Xtant Medical expects full year 2023 revenue of $73 million to $75 million, representing annual growth of approximately 26% to 29% compared to full year 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453593/000149315223015373/0001493152-23-015373-index.htm
- Earnings Releases
  Xtant Medical Holdings, Inc. reported first quarter ended March 31, 2023 results: revenue $17.9 million, net income $2.1 million, or $0.02 per share, EPS $0.02 per share.
  - Period: first quarter ended March 31, 2023
  - Revenue: $17.9 million
  - Net income: $2.1 million, or $0.02 per share
  - EPS: $0.02 per share
  - Result: reported results
  source text: 2023 Financial Results First quarter 2023 revenue grew 38%, including organic growth of 29% and a 9% contribution from the acquisition of the Coflex and CoFix product lines, to $17.9 million, compared to $13.0 million for the same period in 2022. The increase in revenue was attributed primarily to greater independent agent sales and sales from the recently acquired
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453593/000149315223015373/0001493152-23-015373-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.